Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
60 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Primary care centers
Patients older than 60 years
Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14
Participation in other studies in the last 3 months before the start of the study
Known hypersensibility to venlafaxine
Clinically significant abnormalities according to the venlafaxine labeling